BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12867130)

  • 1. Imatinib or transplant for chronic myeloid leukaemia?
    Craddock C; Augustson B; Basu S
    Lancet; 2003 Jul; 362(9378):173. PubMed ID: 12867130
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib or transplant for chronic myeloid leukaemia?
    Goldman J; Apperley J; Kanfer E; Olavarria E; Marin D
    Lancet; 2003 Jul; 362(9378):172-3. PubMed ID: 12867128
    [No Abstract]   [Full Text] [Related]  

  • 3. Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation.
    Lange T; Bumm T; Mueller M; Otto S; Al-Ali HK; Grommisch L; Musiol S; Franke C; Krahl R; Niederwieser D; Deininger MW
    Leukemia; 2005 Jul; 19(7):1262-5. PubMed ID: 15858618
    [No Abstract]   [Full Text] [Related]  

  • 4. Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.
    Champlin RE; Kantarjian H
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):398-400. PubMed ID: 16258420
    [No Abstract]   [Full Text] [Related]  

  • 5. Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim DW; Chung YJ; Lee S; Kim YJ; Chung NG; Kim JA; Oh IH; Kim TG; Kim YL; Goh HG; Kim SH; Cho B; Kim HJ; Min CK; Lee JW; Jin JY; Han CW; Kim JW; Min WS; Kim HK; Kim CC; Kim HJ
    Leukemia; 2004 Nov; 18(11):1907-9. PubMed ID: 15356641
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.
    Perz JB; Khorashad JS; Marin D; Apperley JF; Olavarria E
    Haematologica; 2006 Aug; 91(8):1145-6. PubMed ID: 16870551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.
    Peggs K; Mackinnon S
    N Engl J Med; 2003 Mar; 348(11):1048-50. PubMed ID: 12637616
    [No Abstract]   [Full Text] [Related]  

  • 8. STI-stop transplanting immediately?
    Klingemann HG
    J Hematother Stem Cell Res; 2002 Apr; 11(2):165-7. PubMed ID: 11983089
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term durability of molecular and chimerism responses in patients treated with imatinib for chronic myeloid leukemia relapse after allogeneic transplantation.
    Martín-Palanco V; Martínez F; Arqueros V; Torres A; Román-Gómez J
    Eur J Haematol; 2011 Aug; 87(2):182-5. PubMed ID: 21762210
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias.
    Tiribelli M; Marin L; Calistri E; Geromin A; Damiani D; Fanin R
    Bone Marrow Transplant; 2004 Nov; 34(9):827-8. PubMed ID: 15334052
    [No Abstract]   [Full Text] [Related]  

  • 11. Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure.
    O'Connor LM; Langabeer S; McCann SR; Conneally E
    Bone Marrow Transplant; 2008 Dec; 42(12):833-5. PubMed ID: 18711344
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma.
    Mughal TI; Goldman JM
    Eur J Cancer; 2001 Mar; 37(5):561-8. PubMed ID: 11290430
    [No Abstract]   [Full Text] [Related]  

  • 13. Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma?
    Thornley I; Perentesis JP; Davies SM; Smith FO; Champagne M; Lipton JM
    Med Pediatr Oncol; 2003 Aug; 41(2):115-7. PubMed ID: 12825214
    [No Abstract]   [Full Text] [Related]  

  • 14. A 41-year-old woman with chronic myelogenous leukemia.
    Antin JH
    JAMA; 2003 Aug; 290(8):1083-90. PubMed ID: 12941682
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic myeloid leukemia--advances in biology and new approaches to treatment.
    Goldman JM; Melo JV
    N Engl J Med; 2003 Oct; 349(15):1451-64. PubMed ID: 14534339
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib.
    Savani BN; Srinivasan R; Espinoza-Delgado I; Dorrance C; Takahashi Y; Igarashi T; Rezvani K; Lundqvist A; Barrett AJ; Childs RW
    Lancet Oncol; 2005 Oct; 6(10):809-12. PubMed ID: 16198987
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard?
    Sausville EA
    Lancet; 2003 Apr; 361(9367):1400-1. PubMed ID: 12727387
    [No Abstract]   [Full Text] [Related]  

  • 18. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
    Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
    Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Barbour V
    Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic myeloid leukemia.
    Singhal N; Bapsy PP; Babu KG; George J
    J Assoc Physicians India; 2004 May; 52():410-6. PubMed ID: 15656033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.